Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- Conditions
- Paget's Disease of Bone
- Interventions
- Drug: Placebo to Zoledronic AcidDietary Supplement: Calcium and Vitamin D
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT00051636
- Locations
- 🇬🇧
Novartis Investigative Site, Vale of Glamorgan, United Kingdom
🇬🇧Novartis investigative site, Pernarth, United Kingdom
🇬🇧Novartis Investigative site, Penarth, United Kingdom
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
- Conditions
- Breast NeoplasmsOsteoporosis
- Interventions
- First Posted Date
- 2002-11-20
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 602
- Registration Number
- NCT00050011
- Locations
- 🇺🇸
FL Community Cancer Center, Brooksville, Florida, United States
🇺🇸Eastern Connecticut Hematology/Oncology Associates, Norwich, Connecticut, United States
🇺🇸Elmhurst Memorial Hospital, Elhurst, Illinois, United States
HORIZON-PFT: Pivotal Fracture Trial
- Conditions
- Osteoporosis
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7700
- Registration Number
- NCT00049829
- Locations
- 🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
- Conditions
- OsteoporosisHip Fracture
- First Posted Date
- 2002-09-25
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2127
- Registration Number
- NCT00046254
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
🇺🇸Radiant Research Lake Worth, Lake Worth, Florida, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
- Conditions
- Prostate Cancer
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT00035997
- Locations
- 🇺🇸
Urology Associates of Central CA, Fresno, California, United States
🇺🇸Advanced Urology Medical Office, Los Angeles, California, United States
🇺🇸Southwest Florida Urologic Association, Fort Myers, Florida, United States
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
- Conditions
- Breast CancerMultiple MyelomaProstate Cancer
- First Posted Date
- 2002-01-10
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 500
- Registration Number
- NCT00029224
- Locations
- 🇺🇸
Osceola Cancer Center, Kissimmee, Florida, United States
🇺🇸Stockton Hematology Oncology Medical Group, Stockton, California, United States
🇺🇸Hematology-Oncology Associates PC, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.